Carmichael Hill & Associates, Inc. Avadel Pharmaceuticals PLC Transaction History

Carmichael Hill & Associates, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 05, 2022	BUY	$1.07 - $6.95 $12,840 - $83,400	12,000 Added 133.33%	21,000 $51,000
Q1 2022 May 16, 2022	BUY	$5.46 - $8.29 $5,460 - $8,290	1,000 Added 12.5%	9,000 $61,000
Q4 2020 Jan 27, 2021	BUY	$5.03 - $7.95 $10,060 - $15,900	2,000 Added 33.33%	8,000 $53,000
Q2 2020 Aug 05, 2020	BUY	$7.25 - $11.75 $14,500 - $23,500	2,000 Added 50.0%	6,000 $48,000
Q4 2019 Jan 30, 2020	BUY	$3.34 - $7.7 $13,360 - $30,800	4,000 New	4,000 $30,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Carmichael Hill & Associates, Inc., based on Form 13F filings with the SEC.

Stay updated on Carmichael Hill & Associates, Inc. with notifications on news.